封面
市场调查报告书
商品编码
1098618

疟疾疫苗的市场规模、占有率、展望、机会 (2022年~2030年):各病原体、疫苗类型、流通管道、地区

Malaria Vaccines Market, by Agent, by Vaccine Type, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 166 Pages | 商品交期: 2-3个工作天内

价格
简介目录

主要企业着重契约等成长策略的采用,预计促进在预测期间内的全球疟疾疫苗市场成长。

本报告提供全球疟疾疫苗的市场调查,市场定义和概要,市场成长的各种影响因素分析,法律制度,开发平台的分析,市场规模的变化、预测,各种区分、各地区/主要国家的明细,竞争环境,主要企业简介等彙整资讯。

目录

第1章 调查目的、前提条件

第2章 市场概要

第3章 市场动态、法规、趋势分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 法规情境
  • 市场趋势
  • 开发平台分析
  • 主要的展开
  • 流行病学
  • PEST分析
  • 联盟、收购
  • 波特五力分析
  • 疫苗的开发週期

第4章 全球疟疾疫苗市场:COVID-19影响

  • 经济影响
  • 需求与供给的影响
  • COVID-19:影响评估

第5章 全球疟疾疫苗市场:各病原体

  • 恶性疟原虫
  • 间日疟原虫
  • 疟蚊种

第6章 全球疟疾疫苗市场:各疫苗类型

  • 前红血球
  • 红血球
  • 多抗原

第7章 全球疟疾疫苗市场:各流通管道

  • 公共
  • 民间

第8章 全球疟疾疫苗市场:各地区

  • 北美
  • 南美
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第9章 竞争情形

  • 热图分析
  • 市场占有率分析
    • GlaxoSmithKline
    • Nobelpharma
    • Sanaria
    • CellFree Sciences
    • VLP Therapeutics LLC
    • Sumaya Biotech
    • BioNTech
    • Precigen, Inc

第10章 Section

简介目录
Product Code: CMI37

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. Malaria vaccines are used to prevent the spread of malaria. The only approved vaccine, as of 2021, is RTS,S, known by the brand name Mosquirix. In October 2021, the World Health Organization (WHO) for the first time recommended the large-scale use of a malaria vaccine for children living in areas with moderate-to-high malaria transmission. Four injections of malaria vaccines are required for full protection.

Market Dynamics

Key players operating in the global malaria vaccine market are focusing on adoption of growth strategies such as agreements which are expected to drive market growth during the forecast period. For instance, in January 2021, GlaxoSmithKline (GSK), a science-led global healthcare company, PATH (Program for Appropriate Technology in Health), nonprofit global health organization based in Seattle, U.S., and Bharat Biotech (BBIL), is an Indian multinational biotechnology company announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E. The agreement includes, transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL. Moreover, increasing research and development for malaria vaccine is expected to propel the global malaria vaccine market over the forecast period. For instance, in April 2021, scientists at the University of Oxford's Jenner Institute announced that their Phase IIb trial of a candidate malaria vaccine achieved 77% efficacy in early stage trials - making it the first malaria vaccine to meet the WHO's target of 75%. The Phase IIb trial of the vaccine candidate, R21, enrolled 450 children in Burkina Faso, one of the 10 countries with the highest cases of malaria and subsequent deaths.

Key features of the study:

  • This report provides in-depth analysis of the global malaria vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Global Malaria vaccine Market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include GlaxoSmithKline, Nobelpharma, Sanaria, CellFree Sciences, VLP Therapeutics LLC, Sumaya Biotech, BioNTech, and Precigen, Inc
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Global Malaria vaccine Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global malaria vaccine market.

Detailed Segmentation:

  • Global Malaria vaccine Market, By Agent :
    • Plasmodium Falciparum
    • Plasmodium Vivax
    • Anopheles Species
  • Global Malaria vaccine Market, By Vaccine Type :
    • Pre-Erythrocytic
    • Erythrocytic
    • Multi-antigen
  • Global Malaria vaccine Market, By Distribution Channel :
    • Public
    • Private
  • Global Malaria vaccine Market, By Region:
    • North America
      • By Country
      • U.S.
      • Canada
    • Latin America
      • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Country
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Country
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • GlaxoSmithKline.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Nobelpharma
    • Sanaria
    • CellFree Sciences
    • VLP Therapeutics LLC
    • Sumaya Biotech
    • BioNTech
    • Precigen, Inc

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Agent
    • Market Snapshot, By Vaccine Type
    • Market Snapshot, By Distribution Channels
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunity
  • Impact Analysis
  • Regulatory Scenario
  • Market Trends
  • Pipeline Analysis
  • Key Developments
  • Epidemiology
  • PEST Analysis
  • Collaboration and Acquisition
  • Porters Analysis
  • Vaccine Developmental Cycle

4. Global Malaria Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

  • Economic Impact
  • Impact on Demand and Supply
  • COVID-19 Impact Assessments

5. Global Malaria Vaccines Market, By Agent, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Plasmodium Falciparum
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Plasmodium Vivax
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Anopheles Species
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Malaria Vaccines Market, By Vaccine Type, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Pre-Erythrocytic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  • Erythrocytic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  • Multi-antigen
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

7. Global Malaria Vaccines Market, By Distribution Channel, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Public
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  • Private
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

8. Global Malaria Vaccines Market, By Region, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • GlaxoSmithKline
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Nobelpharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Sanaria
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • CellFree Sciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • VLP Therapeutics LLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Sumaya Biotech
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • BioNTech
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Precigen, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies

10. Section

  • Research Methodology
  • About us